Evidence map›Paper›PMID 41259666›Full record

ArticleJournal of Crohn's & colitis2025

Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease: endo-histo-barrier-omics study.

Marietta Iacucci, Snehali Majumder, Irene Zammarchi, Giovanni Santacroce, Ivan Capobianco, Cecilia Lina Pugliano, Ujwala Chaudari, Pablo Meseguer Esbri, Brian Hayes, Rory Crotty and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. New Technologies for IBD Endoscopy.Journal of clinical medicine · 2026
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marietta IacucciAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.ORCID 0000-0002-3142-9550
Snehali MajumderAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Irene ZammarchiAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Giovanni SantacroceAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.ORCID 0000-0002-0544-0414
Ivan CapobiancoAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.ORCID 0000-0003-3927-591X
Cecilia Lina PuglianoAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.ORCID 0009-0009-6043-3231
Ujwala ChaudariSchool of Engineering, London South Bank University, London, United Kingdom.
Pablo Meseguer EsbriInstituto de Investigación e Innovación en Bioingeniería, HUMAN-Tech, Universitat Politècnica de València, València, Spain.
Brian HayesDepartment of Histopathology, Cork University Hospital, Cork, Ireland.
Rory CrottyDepartment of Histopathology, Cork University Hospital, Cork, Ireland.
Maria R AburtoAPC Microbiome Ireland, Department of Anatomy and Neuroscience-School of Medicine, University College Cork, Cork, Ireland.
Maria Rocio Del AmorInstituto de Investigación e Innovación en Bioingeniería, HUMAN-Tech, Universitat Politècnica de València, València, Spain.
Bisi Bode KolawoleSchool of Engineering, London South Bank University, London, United Kingdom.
Julia EckenbergerAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Asma AmamouAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Valery NaranjoInstituto de Investigación e Innovación en Bioingeniería, HUMAN-Tech, Universitat Politècnica de València, València, Spain.
Enrico GrisanSchool of Engineering, London South Bank University, London, United Kingdom.
Subrata GhoshAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.ORCID 0000-0002-1713-7797
Endo-Histo-Barrier-Omics Group

Funding

University College Cork (UCC)
6 · The paper itself

Abstract

backgroundBarrier healing is an emerging therapeutic target in inflammatory bowel disease (IBD), though its assessment remains challenging. We evaluated automated advanced imaging for real-time barrier assessment, its correlation with epithelial/vascular barrier markers, and ability to predict adverse outcomes.

methodsIBD patients and healthy controls undergoing endoscopic assessment were prospectively enrolled. The intestinal barrier was evaluated using ultra-high-magnification endocytoscopy and probe-based confocal laser endomicroscopy. Targeted biopsies were obtained from inflamed and non-inflamed segments. Epithelial and vascular barriers were assessed through automated multiplex immunofluorescence for Claudin-2, ZO-1, E-cadherin, PV-1, and CD31. Gene expression profiling was performed in epithelial and lamina propria compartments. Artificial intelligence (AI)-based analysis was employed for automated evaluation of barrier features captured by advanced imaging.

resultsIn total, 103 patients were included (38 ulcerative colitis [UC], 54 Crohn's disease [CD], 11 healthy controls). Advanced imaging revealed barrier healing in 21% (8/38) of UC and 30% (16/54) of CD patients. In UC, Claudin-2 moderately correlated with abnormal crypt architecture (ρ = 0.49), goblet cell depletion (ρ = 0.5), and overall endocytoscopy activity (ρ = 0.49). In CD, PV-1 moderately correlated with altered blood flow (ρ = 0.41) and vessel architecture (ρ = 0.40). An integrated assessment of advanced imaging, combined with Claudin-2 and PV-1 expression, effectively predicted adverse outcomes in UC and CD, respectively. AI tools accurately classified epithelial and vascular barrier features captured by advanced imaging. Finally, gene expression confirmed upregulation of Claudin-2 and PV-1 in IBD.

conclusionAutomated advanced imaging enables real-time barrier assessment in IBD and correlates with markers of epithelial and vascular barrier impairment. AI integration can enhance standardization toward broader clinical applicability.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesIntestinal MucosaAdultArtificial IntelligenceCase-Control StudiesClaudin-2FemaleGene Expression ProfilingHumansMaleMicroscopy, ConfocalMiddle AgedProspective StudiesClaudin-2advanced imagingartificial intelligencebarrier impairmentClaudin-2gene expressionmultiplex immunofluorescencePV-1

Identifiers

PMID41259666
PMCPMC12701889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.